Drug Detail

Information about Velcade + Sutent

Generic Name	Bortezomib + Sunitinib
IND	Bortezomib + Sunitinib
Brand Name (US)	Velcade + Sutent
Manufacturer	Millennium
Drug Type	Proteasome Inhibitor + Tyrosine Kinase Inhibitor
Delivery	Intravenous + Oral
Approval Status	Both are approved. This combination is not approved for GIST. It was evaluated in a phase 1 trial for non-GIST cancers.
Indications
Overall Strategy	KIT Protein Based + Oncogenic Signal Path Based
Strategy	Activate death receptors + Block KIT
Drug Category	Proteasome inhibitor

Sunitinib (Sutent) is approved for 2nd line treatment of GIST. Bortezomib (Velcade) is approved for multiple myeloma. Bortezomib has shown activity against GIST cells in lab experiments, but has not been tested against GIST in a clinical trial.